Simcere and Boao Evergrande International Hospital cooperate to use Trilaciclib for the first clinical treatment of Chinese patients

On June 2, 2021, Trilaciclib, a new bone marrow-protecting drug approved by the FDA as a breakthrough therapy, issued its first prescription in the Hainan Boao Lecheng Medical Pilot Area, and completed the first clinical administration.

Trilaciclib was approved for marketing in the United States in February 2021.

Prior to this, Simcere and Trilaciclib's research and development company G1 Therapeutics reached a cooperation and obtained Trilaciclib's development and commercialization rights for all indications in Greater China (Mainland China, Hong Kong, Macau and Taiwan).

Clinical needs for bone marrow protection remain to be met

At present, the cornerstone of most tumor treatment programs is still chemotherapy, but the side effects of chemotherapy are more prominent.

Bone marrow is the manufacturing center of various types of blood cells (red blood cells, white blood cells and platelets) in the human body.

Bone marrow suppression not only reduces the patient's quality of life, but also leads to a reduction or delay in the administration of chemotherapy drugs, reducing the anti-tumor effect of chemotherapy.

For patients with extensive-stage small cell lung cancer, the problem of bone marrow suppression is particularly prominent.

At present, the main clinical measures to deal with bone marrow suppression include the use of hematopoietic growth factors, blood transfusion (red blood cells, platelets), etc.

Is there a way to prevent CIM during chemotherapy without reducing the anti-tumor efficacy?

The first domestic prescription for preventive new drugs

Trilaciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor developed by G1 Therapeutics.

In terms of the mechanism of action, Trilaciclib can temporarily maintain the G1 cell cycle arrest of HSPC in the bone marrow, protect cells from cytotoxic drugs, and improve the tumor immune microenvironment when combined with chemotherapy.

Figure: Trilaciclib can reduce the incidence of multi-cell line myelosuppression in patients with 1~3L SCLC [2]

(Analysis of combined data of 3 randomized double-blind placebo-controlled trials)

At present, Trilaciclib has carried out a number of clinical trials overseas, including triple negative breast cancer (TNBC), metastatic colorectal cancer (mCRC), etc.

This clinical application is not only an attempt of the product in the domestic patient population, but also will provide real-world evidence for Trilaciclib to be used in more Chinese patients in the future.

references:

[1] Zhou, S.

[2] Weiss et al.